Related references
Note: Only part of the references are listed.Comparison of efficacy of HCAG and CAG re-induction chemotherapy in elderly low- and intermediate-risk group patients diagnosed with acute myeloid leukemia
J. Y. Zhang et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC
Chenying Li et al.
HAEMATOLOGICA (2020)
Co-delivery of homoharringtonine and doxorubicin boosts therapeutic efficacy of refractory acute myeloid leukemia
Doudou Yan et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-κB repressing factor
Xin-Jie Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice
Jeannette Cany et al.
BLOOD (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia
Jens Przybilla et al.
EPIGENETICS (2017)
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
Marilyn M. Li et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition
Aroa Baragano Raneros et al.
ONCOTARGET (2017)
Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis
Pin-Fang He et al.
ONCOTARGET (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1 a cells
Suxia Geng et al.
LEUKEMIA RESEARCH (2016)
HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants
Mixue Xie et al.
PLOS ONE (2016)
Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein
Jiang Cao et al.
CANCER MEDICINE (2016)
Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
Navneet S. Majhail et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Effectiveness of Homoharringtonine (Omacetaxine Mepesuccinate) for Treatment of Acute Myeloid Leukemia: A Meta-Analysis of Chinese Studies
Hagop Kantarjian et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
Jianyong Li et al.
ONCOTARGET (2015)
Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia
A. Baragano Raneros et al.
GENES AND IMMUNITY (2015)
Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia
Jie Jin et al.
LEUKEMIA & LYMPHOMA (2015)
Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment
Roland B. Walter et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
Guoqing Wei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Hugo F. Fernandez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Clinical and molecular cytogenetic studies in seven patients with myeloid diseases characterized by i(20q-)
TY Li et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)